Philip Hemme, Author at Labiotech.eu

About

Young French-German Entrepreneur, Co-founder & CEO of Labiotech.eu. High-level table tennis player, and German beer/French Wine lover 🙂

Articles by Philip Hemme

Best in Biotech 22 Jun 2016

11 Biotech Leaders you should meet in Munich

I guess you’ve read some of our tops lately (VCs, Paris, Unicorns). Those were mainly about specific companies or regions. Now, we wanted to try a new format and focus on people instead. For this first edition, we decided to focus on Munich, one of Europe’s top biotech regions. I asked some biotech leaders in Munich […]

June 22, 2016 - 5 minutesmins - By Philip Hemme

News and Trends 20 Jun 2016

Meet the Biotech successfully using Bacteria for Immuno-Oncology

Yes, the title may have surprised you, but it’s true. Vaximm is one of the few biotechs worldwide using bacteria to activate the immune system against cancer. I was really surprised about how elegant the technology is when I had a chat with the Executive Chairman Klaus Breiner at BioEquity in Copenhagen. Vaximm is based in Basel […]

June 20, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 16 Jun 2016

This German Diagnostic company was sold for €50M to the World leading Molecular Diagnostic company

Sividon was a spin-off from Siemens, founded in July 2011 – and it was just sold to the American Myriad Genetics ($2.2Bn market cap) for €50M, even though the company raised only €5M over its lifetime. A clear success story that I discussed with Karlheinz Schmelig, partner of Sividon’s Lead investor Creathor Venture. Sividon worked in […]

June 16, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 31 May 2016

DBV Technologies: “This is our First and most Significant Partnership signed”

The billion-euro Biotech from Paris DBV Technologies just signed a €100M deal with Nestlé Health Science to develop a new diagnostic test of Milk allergies. This is the first deal of DBV and shows the potential of its technological platform. I had a chat with its COO David Schilansky to find out more… DBV is […]

May 31, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 28 May 2016

What Happened this Week? Refresh, Virtual Biotech, Bayer and Monsanto

1. So that was Labiotech Refresh! Here are the conference Highlights 2. To Be – or Not To Be, a Virtual Biotech? 3. Bayer offers Big Buy out for the infamous Monsanto. Shareholders are not pleased… 4. Even after Quarantine, Ebola still transmitted by Breastfeeding and Sex 5. French T-cell Expert restarts trial for Crohn’s after Manufacturing Hiccup […]

May 28, 2016 - 1 minutemin - By Philip Hemme

poland obama selvita epibiome microbiome ardigen

News and Trends 18 May 2016

Polish Bioinformatics company backs US movement into Microbiome Research

In Kraków, the Bioinformatics company Ardigen has now partnered up with a US based Microbiome startup, EpiBiome, which is looking for the answer to antibiotic resistance. This is another example of cross-Atlantic collaboration in the Microbiome world, just as President Obama pledges €105M ($121M) to the up and coming field of therapeutics. It’s a growing area of research, and as […]

May 18, 2016 - 2 minutesmins - By Philip Hemme

seventure microbiome labiotech biotech fund eligo enterome microbiomics medicine

News and Trends 16 May 2016

Interviewing the Founder of the World #1 Microbiome Investment fund

Isabelle De Cremoux is the CEO and President of French VC fund Seventure Partners, famous for having opened Health for Life Capital, a €160M fund dedicated to the Microbiome. Having previously worked in the business development team of Pfizer as well as Fournier/Abbott, Isabelle created the lifesciences department when joining Seventure, which she manages as CEO […]

May 16, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 14 May 2016

What Happened this Week? Lupus fight, CRO, Plant charger

1. Today is World Lupus Day! Meet the people who are fighting this Rare disease 2. This UK Company told us how they Optimise Drug Development and turn a Profit 3. Meeting the startup which uses Plants to charge your Smartphone 4. This Dutch Gene Therapy is on the shelf and seems to Work. But nobody is […]

May 14, 2016 - 1 minutemin - By Philip Hemme

biotech nathalie moll europabio biotechnology

News and Trends 11 May 2016

EuropaBio: “We as an industry should be proud of what we do”

We just partnered with the European Biotech Week, which is a good reason to talk to its secretary general, Nathalie Moll. I asked her more about the event, the reasons for organising it and her vision for the future of Biotech in Europe. The event is a week of Biotech related seminars and activities from September 26th to October 2nd organised by […]

May 11, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 7 May 2016

What happened this week? Copenhagen Biotechs, Bio-lighting, China

1. Here are 12 Biotechs you need to know in Copenhagen – Skål! 2. ‘First Blood Test for Colorectal Cancer is One of the most Innovative Medical Products’ says Chinese FDA 3. Feel like investing in Bio-Lighting? Here’s your chance 4. What’s the Vatican doing with Biotech? Awarding Billionaire Doctors for Cancer & Stem Cell Research 5. Genetic Diagnostic […]

May 7, 2016 - 1 minutemin - By Philip Hemme

News and Trends 30 Apr 2016

What happened this week? Biotech Pyramid, CEO Interviews, Anti-Ageing

1. Infographic: Which are the most Valuable Biotechs in Europe? 2. Interviewing the CEO who uses Probiotics as Needle-free Vaccines 3. Illumina is Suing over NGS Prenatal Screening… Again 4. Interviewing the CSO of the newly £100Bn fund willing to finally tackle Dementia 5. Anti-ageing DIY Gene Therapy may have worked – to an extent… 6. ITW with the […]

April 30, 2016 - 1 minutemin - By Philip Hemme

interview biotrinity labiotech dementia fund

News and Trends 28 Apr 2016

Interviewing the CSO of the newly €90M fund willing to finally tackle Dementia

I had the chance to talk with Tetsuyuki Maruyama, the CSO of the relatively new Dementia Discovery Fund – our final interview for #BioTrinity2016 in London. The high risk nature of doing trials for Dementia patients means in the past the market for this area of Neurodegenerative disease has been tough. However, the need for […]

April 28, 2016 - 1 minutemin - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us